Microbot’s Liberty Robotic System Evaluated in ACCESS-PVI Pivotal Trial

April 9, 2025—Microbot Medical Inc., a precommercial-stage medical technology company that is developing the Liberty endovascular robotic system, announced that data from its ACCESS-PVI pivotal trial was presented for the first time.

The company stated that the ACCESS-PVI study was conducted at Memorial Sloan Kettering Cancer Center in New York, New York; Baptist Hospital of Miami in Miami, Florida; and Brigham and Women’s Hospital in Boston, Massachusetts.

Francois Cornelis, MD, delivered the data in a late-breaking podium presentation at SIR 2025, the Society of Interventional Radiology’s 50th annual scientific meeting held March 29 to April 2 in Nashville, Tennessee. Dr. Cornelis is Director of the Neuro Vascular Interventional Radiology Program at Memorial Sloan Kettering Cancer Center.

According to Microbot Medical, the data presented at SIR showed that robotic endovascular procedures using the Liberty device are feasible and significantly minimize radiation exposure.

The company’s press release outlined the following highlights of the ACCESS-PVI study:

• Successful robotic navigation was achieved in every case (N = 20). The 100% success rate met the primary endpoint of the study.
• No adverse device events were reported through the duration of follow-up.
• Mean difference in radiation exposure between operator and control was (-) 29.8 µS, resulting in a mean 92% relative reduction in radiation exposure.
• Median robotic navigation time to target was 3 minutes.
• Participating physicians reported Liberty performed as planned with a 100% satisfaction rate.

Liberty is an investigational device pending FDA 510(k) clearance and is currently not available for sale in the United States, advised Microbot. In December 2024, the company announced it had submitted a 510(k) premarket notification to the FDA for the Liberty system.